natgillin/translations-raw huggingface dataset:
Peyronie’s disease occurs exclusively in adult male patients and hence there is no relevant use of Xiapex in the paediatric population aged 0-18 years for the treatment of Peyronie’s disease.
Peyronijeva bolest nastaje isključivo kod odraslih muških bolesnika i zato nema odgovarajuće primjene Xiapexa u pedijatrijskoj populaciji u dobi od 0 do 18 godina za liječenje Peyronijeve bolesti.
Peyronie’s Disease Questionnaire (PDQ)b, – Mean Patient-Reported PD Bother Domain Score (range: 0-16) c
Upitnik za Peyronijevu bolest (PDQ)b, – Srednji broj bodova u dijelu "tegobe" zabilježen od strane bolesnika (raspon: 0-16) c
Peyronie’s disease: The treatment area should be identified and marked with a surgical marker on the erected penis.
Peyronijeva bolest: Potrebno je odrediti područje za liječenje i obilježiti ga kirurškim flomasterom na penisu u erekciji.
Peyronie’s plaque
Peyronijev plak
Pfizer AB
Pfizer Oy
Pfizer AS
Pfizer bv
Pfizer Biofarmacêutica, Sociedade Unipessoal Lda Tel: +351 21 423 5500
Pfizer Polska Sp. z o.o.
Pfizer bv
V.J. Salomone Pharma Ltd.
Pfizer Corporation Austria Ges.m.b.H.
Pfizer ΕΛΛΑΣ A.E. Pfizer Corporation Austria Ges.m.b.H.
Pfizer Innovations AB Tel: +46 (0)8 550 520 00
Pfizer Innovation AB Tel: +46 (0)8 550 520 00
Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Ireland.
Pfizer Ireland Pharmaceuticals, Little Connell, Newbridge, County Kildare, Irska.
Pfizer Kft.
Pfizer S.A.
Pfizer Limited
Pfizer AB
Pfizer Limited (as MA Holder logo)
Pfizer Limited (kao logotip nositelja odobrenja)
Pfizer Limited Ramsgate Road
Pfizer Limited Ramsgate Road,
Pfizer Limited Ramsgate Road Sandwich
Pfizer Limited Wyeth Pharmaceuticals
Pfizer Limited Ramsgate Road Sandwich
Pfizer Limited, Ramsgate Road, Sandwich,
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, United Kingdom
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, Ujedinjeno Kraljevstvo
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Ramsgate Rd, Sandwich, Kent, CT13 9NJ, Velika Britanija.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Ujedinjeno Kraljevstvo
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Ujedinjeno Kraljevstvo.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Velika Britanija.
Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent CT13 9NJ, Ujedinjeno Kraljevstvo.
Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent CT13 9NJ, Velika Britanija.
Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent CT13 9NJ, Ujedinjeno Kraljevstva.
Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent CT13 9NJ, Ujedinjeno Kraljevstvo.
Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.
Pfizer Limited, Sandwich, Kent, CT13 9NJ, Velika Britanija.
Pfizer Ltd (as MA Holder logo)
Pfizer Ltd (kao logo Nositelja odobrenja)
Pfizer Ltd (as MA Holder logo)
Pfizer Ltd (logo nositelja odobrenja)
Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
Pfizer Innovations AB Tel: +46 (0)8 550-52000
Pfizer Luxembourg SARL filiāle Latvijā Tel: +371 670 35 775
Pfizer Luxembourg SARL filiāle Latvijā Tel: +371 670 35 77
Pfizer Luxembourg SARL, organizačná zložka Tel: +421–2–3355 5500
Pfizer Luxembourg SARL, Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
Pfizer Manufacturing Belgium N.V. Rijksweg 12
Pfizer Manufacturing Belgium N.V. Riijsweg 12
Pfizer PFE, spol. s r.o.
Pfizer PFE, spol. s.r.o.
Pfizer Pfizer România S.R.L.
Pfizer Pfizer Biofarmacêutica, Sociedade Unipessoal Lda
Pfizer Polska Sp. z o.o.
Pfizer Corporation Austria Ges.m.b.H.
Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 00
Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 00
Pfizer România S.R.L. Tel: +40 (0)21 207 28 00
Pfizer Biofarmacêutica, Sociedade Unipessoal Lda
Pfizer S.L.
Pfizer
Pfizer S.r.l.
Pfizer IS.r.l.
Pfizer Service Company, Hoge Wei 10, B1930 Zaventem, Belgium
Pfizer Service Company, Hoge Wei 10, B1930 Zaventem, Belgija.
Pfizer ΕΛΛΑΣ A.E.
Pfizer ΕΛΛΑΣ A.E. Τηλ.: +30 210 6785 800
PFIZER ΕΛΛΑΣ A.E., Τλ: +30 210 67 85 800
PFIZER ΕΛΛΑΣ A.E. Τλ: +30 210 67 85 800
Pfizer ΕΛΛΑΣ Α.Ε. (Cyprus Branch)
Pfizer ΕΛΛΑΣ Α.Ε. (Cyprus Branch)Τηλ:
Pfizer Ελλάς A.E. (Cyprus Branch) Tηλ: +357 22 817690
Pfizer Ελλάς (Cyprus Branch) A.E. Tηλ: +357 22 817690
Pfizer Ελλάς A.E. (Cyprus Branch) Tηλ: +357 22 817690
Pfizer Ελλάς A.E.(Cyprus Branch) Tηλ: +357 22 817690
PFS (median in months), Investigator assessed
PFS (medijan u mjesecima), Prema procjeni ispitivača
PFS (median)
PFS (medijan)
PFS - overall Median (months)e (95% CI)d
PFS – ukupno Medijan (mjeseci)e (95% CI)d
PFS = progression-free survival; CI = confidence interval.
PFS = preživljenje bez progresije; CI = interval pouzdanosti.
PFS according to a post-hoc, blinded, independent assessment was 8.2 months vs
PFS prema post-hoc ocjeni zaslijepljenog neovisnog povjerenstva iznosio je 8,2 mjeseca naspram 4,4 mjeseca; HR = 0,670; p = 0,1208.
PFS benefit was accompanied by improvement in disease-related symptoms and delayed time to deterioration (see Table 7).
Korist u PFS-u bila je popraćena poboljšanjem simptoma izazvanih bolešću, te odgodom vremena do pogoršanja (vidjeti tablicu 7).
PFS benefit was accompanied by improvement in disease-related symptoms and delayed time to deterioration (see Table 9).
Korist u PFS-u bila je popraćena poboljšanjem simptoma izazvanih bolešću, te odgodom vremena do pogoršanja (vidjeti tablicu 9).
PFS data from Study 1005 included 807 patients in the safety analysis population who were identified by the FISH assay (data cutoff date 15 February 2012).
Podaci o PFS-u i OS-u iz Ispitivanja 1005 uključivali su 807 bolesnika u analizi sigurnosnih podataka populacije utvrđenih testom FISH (zaključni datum prikupljanja podataka 15. veljače 2012.).
PFS data were partially confirmed by an independent review (400 / 1725 patients were randomly selected for review).
Podaci za PFS djelomično su potvrđeni neovisnom procjenom (400/1725 bolesnika bilo je nasumce odabrano za procjenu).
PFS months median (95% CI)
PFS u mjesecima, medijan (95% CI)
PFS rate at 12 months and 95% CI: 42% (36, 47)
Stopa PFS-a nakon 12 mjeseci i 95% CI: 42% (36, 47)
PFS rate at 12 months and 95% CI: 49% (44, 55)
Stopa PFS-a nakon 12 mjeseci i 95% CI: 49% (44, 55)
PFS rate at 6 months
Stopa PFS-a nakon 6 mjeseci
PFS results are shown in Figure 2 (all randomised population), Figure 3 (at the tumour PD-L1 5% cut-off), and Figure 4 (at the tumour PD-L1 1% cut-off).
Rezultati za PFS prikazani su na Slici 2 (cjelokupna randomizirana populacija), Slici 3 (granična vrijednost tumorske ekspresije PD-L1 od 5%) i Slici 4 (granična vrijednost tumorske ekspresije PD-L1 od 1%).
PFS subgroup analyses by disease stage and debulking status are summarised in Table 17.
Analize preživljenja bez progresije bolesti po podskupinama prema stadiju bolesti i statusu smanjenja tumorske mase sažeti su u Tablici 17.
PFS was defined as the time from randomisation to the earliest date of disease progression or death from any cause, or to the date of censor.
Preživljene bez progresije (PFS) bolesti definirano je kao vrijeme od randomizacije do datuma najranije progresije bolesti ili smrti zbog bilo kojeg uzroka ili do datuma cenzure.
PFS was significantly longer in patients receiving Stivarga plus BSC (hazard ratio: 0.494, p<0.000001, see Table 6).
Preživljenje bez progresije bolesti bilo je značajno dulje u bolesnika koji su primali lijek Stivarga uz najbolju potpornu njegu (omjer hazarda: 0,494, p<0,000001, vidjeti tablicu 6).
PFS was statistically significantly improved in patients receiving Cyramza plus docetaxel compared with those receiving placebo plus docetaxel (HR 0.762; 95% CI: 0.677 to 0.859; p<0.001).
PFS se statistički značajno poboljšao u bolesnika liječenih lijekom Cyramza plus docetakselom u odnosu na one koji su primali placebo i docetaksel (HR 0,762; 95% CI: 0,677 do 0,859; p<0,001).
PFS, mediana [95% CI]b (weeks) Sequential HR [95% CI]e Sequential log-rank test, p-valuee
PFS, medijana [95% CI]b (tjedni)
PFS2  (months) ¤
PFS2 (mjeseci) ¤
PFS2e  (months)
PFS2e (mjeseci)
PFS: progression-free survival; EFS: event-free survival; OS: overall survival; TNLT: time to next anti-lymphoma treatment; TNCT: time to next chemotherapy treatment; ORR: overall response rate; NR: not reached at time of clinical cut-off, OR: odds ratio.
PFS: preživljenje bez progresije bolesti; EFS: preživljenje bez pojave događaja; OS: ukupno preživljenje; TNLT: vrijeme do sljedećeg liječenja limfoma; TNCT: vrijeme do sljedeće kemoterapije; ORR: stopa ukupnog odgovora na liječenje: ND: nije dosegnuto u vrijeme prekida kliničkog promatranja; OŠ: omjer šansi
PFS^ (months)
PFS^ (mjeseci)
PFU: plaque forming units
PFU: eng. plaque forming units – jedinice koje tvore plakove.
PFU: plaque forming units.
PFU: eng. plaque forming units – jedinice koje tvore plakove.
PGA of Cleared (0)
PGA čist (0)
PGA of cleared (0), PASI 90).
PGA čisti (0), PASI 90).
PGA of cleared or minimal N (%)
PGAb pročišćenog ili s minimalnog N (%)
PGA: Clear/minimalc
PGA: bez bolesti/minimalnoc
PGAb of cleared or minimal N (%)
PGAb pročišćenog ili minimalnog N (%)
Ph+ ALL (starting dose 600 mg)
KML u blastičnoj krizi i Ph+ ALL (početna doza 600 mg)
Ph+ cells) and partial (1% to 35% Ph+ cells) cytogenetic responses. b Measured in peripheral blood.
Ph+ ne mogu se uočiti) i parcijalne (1% do 35% Ph+ stanica) citogenetičke odgovore. b Mjereno u perifernoj krvi.
Ph+ CP CML
Ph+ CP KML
Ph+ means that some of the patient’s genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome that leads to the development of leukaemia.
Ph+ znači da su se neki od bolesnikovih gena prerasporedili i stvorili poseban kromosom zvan Philadelphia kromosom koji uzrokuje razvoj leukemije.
Ph+ means that some of the patient’s genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase, that leads to the development of leukaemia.
Ph+ znači da su se određeni geni preraspodijelili tako da tvore poseban kromosom nazvan Philadelphia kromosom koji stvara enzim Bcr-Abl kinazu koji rezultira razvojem leukemije.
Ph.
Ph.
Phadisco Ltd
Phadisco Ltd.
Phaeochromocytoma
Feokromocitom
phaeochromocytoma (a tumour of the adrenal gland);
feokromocitomom (tumorom adrenalne žlijezde);
phaeochromocytoma (a tumour of the adrenal gland); a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres).
feokromocitomom (tumorom nadbubrežne žlijezde); anamnezom neuroleptičkog malignog sindroma (opasni poremećaj živčanog sustava uzrokovanog antipsihoticima) ili rabdomiolize (razgradnja mišićnih vlakana).
Phamacovigilance system
Farmakovigilancijski sustav
Pharma Aripiprazole Mylan
Aripiprazole Mylan Pharma Aripiprazole
Pharma Aripiprazole Mylan
Mylan Pharma
Pharma Aripiprazole Mylan
Mylan Pharma Aripiprazole
Pharma Mar, S.A.
Pharma Mar S.A.
Pharma- ceutical form
Farmaceutski oblik
PHARMAC EUTIC AL PARTIC ULARS
FARMACEUTSKI PODACI
PharmaCell Oxfordlaan 70
Oxfordlaan 70
Pharmaceuti cal Form
Farmaceutsk i oblik
Pharmaceuti cal form
Farmaceutski oblik
Pharmaceutical
Farmaceutski
Pharmaceutical
Farmaceutski oblik
Pharmaceutical Form
(Zaštićeno) ime Jakost Farmaceutski oblik
PHARMACEUTICAL FORM
Doziranje i način primjene
Pharmaceutical Form
Farmaceutsk i oblik
Pharmaceutical Form
Farmaceutska forma
Pharmaceutical Form
Farmaceutski
PHARMACEUTICAL FORM
FARMACEUTSKI OBLIK FARMACEUTSKI OBLIK
PHARMACEUTICAL FORM
FARMACEUTSKI OBLIK:
Pharmaceutical Form
Farmacutski oblik
Pharmaceutical Form
Ivemend
Pharmaceutical Form
tablete
PHARMACEUTICAL FORM AND CONTENT
FARMACEUTSKI OBLIK I SADRŽAJ
PHARMACEUTICAL FORM AND CONTENTS
FARMACEUTSKI OBLIK I SADRŢAJ
PHARMACEUTICAL FORM AND CONTENTS
FARMACEUTSKI OBLIK I SADRŽAJ
PHARMACEUTICAL FORM Concentrate for solution for infusion Clear and colourless solution.
FARMACEUTSKI OBLIK Koncentrat za otopinu za infuziju Bistra i bezbojna otopina.
PHARMACEUTICAL FORM Concentrate for solution for infusion.
FARMACEUTSKI OBLIK Koncentrat za otopinu za infuziju.
PHARMACEUTICAL FORM Film-coated tablet (tablet) Fycompa 2 mg film-coated tablets
FARMACEUTSKI OBLIK Filmom obložena tableta (tableta) Fycompa 2 mg filmom obložene tablete
PHARMACEUTICAL FORM Film-coated tablet Marixino 10 mg film-coated tablets
FARMACEUTSKI OBLIK Filmom obložena tableta Marixino 10 mg filmom obložene tablete
PHARMACEUTICAL FORM Hard capsule.
FARMACEUTSKI OBLIK Tvrda kapsula.
PHARMACEUTICAL FORM Lyophilisate and solvent for solution for injection.
FARMACEUTSKI OBLIK Liofilizat i otapalo za otopinu za injekciju.
PHARMACEUTICAL FORM Oral suspension.
FARMACEUTSKI OBLIK Oralna suspenzija.
PHARMACEUTICAL FORM Powder and solvent for nebuliser solution.
FARMACEUTSKI OBLIK Prašak i otapalo za otopinu za atomizator.
PHARMACEUTICAL FORM Powder and solvent for solution for infusion.
FARMACEUTSKI OBLIK Prašak i otapalo za otopinu za infuziju.
PHARMACEUTICAL FORM Powder and solvent for solution for injection.
FARMACEUTSKI OBLIK Prašak i otapalo za otopinu za injekciju.
PHARMACEUTICAL FORM Powder for solution for infusion.
FARMACEUTSKI OBLIK Prašak za otopinu za infuziju.
PHARMACEUTICAL FORM Powder for solution for injection.
FARMACEUTSKI OBLIK Prašak za otopinu za injekciju.
PHARMACEUTICAL FORM Powder for suspension for implantation.
FARMACEUTSKI OBLIK Prašak za suspenziju za implantat.
PHARMACEUTICAL FORM Powder for suspension for injection.
FARMACEUTSKI OBLIK Prašak za suspenziju za injekciju.
PHARMACEUTICAL FORM Solution for injection (injection).
FARMACEUTSKI OBLIK Otopina za injekciju (injekcija).
PHARMACEUTICAL FORM Solution for injection in a cartridge.
FARMACEUTSKI OBLIK Otopina za injekciju u ulošku.
PHARMACEUTICAL FORM Solution for injection in cartridge.
FARMACEUTSKI OBLIK Otopina za injekciju u ulošku.
PHARMACEUTICAL FORM Solution for injection or infusion Clear, colourless solution
FARMACEUTSKI OBLIK Otopina za injekciju ili infuziju Bistra, bezbojna otopina
PHARMACEUTICAL FORM Solution for injection or infusion Clear, colourless solution
FARMACEUTSKI OBLIK Otopina za injekciju ili infuziju Bistra, bezbojna otopina.
PHARMACEUTICAL FORM Solution for injection.
FARMACEUTSKI OBLIK Otopina za injekciju.
PHARMACEUTICAL FORM Solution for injection. (FlexTouch).
FARMACEUTSKI OBLIK Otopina za injekciju. (FlexTouch).
PHARMACEUTICAL FORM Solution for injection. (Injection).
FARMACEUTSKI OBLIK Otopina za injekciju. (Injekcija).
PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe.
FARMACEUTSKI OBLIK Suspenzija za injekciju u napunjenoj štrcaljki.
PHARMACEUTICAL PARTICULARS
FARMACEUTSKE POJEDINOSTI
PHARMACEUTICAL PARTICULARS
FARMACUETSKI PODACI
PHARMACEUTICAL PARTICULARS
FARMAKOLOŠKI PODACI
PHARMACEUTICALPARTICULARS
FARMACEUTSKI PODACI
Pharmachemie B.V. Swensweg 5
Pharmachemie B.V. Swensweg 5‌
Pharmachemie BV Swensweg 5
Pharmachemie B.V. Swensweg 5,
Pharmacist educational material
Edukacijski materijali za ljekarnika
Pharmacists - a detailed letter explaining the switch between the two formulations
Ljekarnici – detaljan dopis u kojem je objašnjen prelazak s jedne na drugu formulaciju
Pharmacist’s telephone:
Telefon farmaceuta:
PHARMACO LOGICAL PROPERTIES
FARMAKOLOŠKA SVOJSTVA
Pharmaco-therapeutic group:
Farmakoterapijska skupina:
Pharmaco-therapeutic group: Anti-Parkinson drugs, other dopaminergic agents, ATC code: NO4BX01 Mecahnism of action
Farmakoterapijska skupina: antiparkinsonici, ostali dopaminergici, ATK oznaka: NO4BX01 Mehanizam djelovanja
Pharmaco-therapeutic group: Anti-Parkinson drugs, other dopaminergic agents, ATC code: NO4BX01 Mechanism of action
Farmakoterapijska skupina: antiparkinsonici, ostali dopaminergici, ATK oznaka: NO4BX01 Mehanizam djelovanja
Pharmaco-therapeutic group: Antineoplastic agents, anthracyclines and related substances, ATC code: L01DB01
Farmakoterapijska skupina: Antineoplastični lijekovi, antraciklini i srodne tvari, ATK oznaka: L01DB01
Pharmaco-therapeutic group: antiobesity preparations, excl. diet products, peripherally acting antiobesity products, ATC code A08AB01.
Farmakoterapijska skupina: Pripravci za liječenje pretilosti, isključujući dijetalne pripravke, lijekovi za liječenje pretilosti koji djeluju periferno, ATK oznaka A08AB01.
Pharmaco-therapeutic group: antiviral for systemic use, protease inhibitors ATC code: J05AE03
Farmakoterapijska skupina: antivirotici za sistemnu primjenu, inhibitori proteaza, ATK oznaka: J05AE03
Pharmaco-therapeutic group: ATC Code: A10A D04.
Farmakoterapijska skupina: ATK oznaka: A10A D04.
Pharmaco-therapeutic group: Bacterial and viral vaccines combined, ATC code: J07CA09
Farmakoterapijska skupina: kombinirana bakterijska i virusna cjepiva, ATK oznaka: J07CA09
Pharmaco-therapeutic group: Intermediate acting human insulin analogue.
Farmakoterapijska skupina: analog humanog inzulina srednjedugog djelovanja.
Pharmaco-therapeutic group: Local haemostatics, ATC code: B02BC30
Farmakoterapijska skupina: lokalni hemostatici, ATK oznaka: B02BC30
Pharmaco-therapeutic group: Medicinal products for treatment of bone diseases, bisphosphonate, ATC Code: M05BA06
Farmakoterapijska skupina: Lijekovi za liječenje bolesti kostiju, bisfosfonati, ATK oznaka: M05BA06
Pharmaco-therapeutic group: Medicinal products for treatment of bone diseases, bisphosphonate, ATC Code: M05BA06
Farmakoterapijska skupina: Pripravci za liječenje bolesti kostiju,bisfosfonati, ATK oznaka: M05BA06
Pharmaco-therapeutic group: Vaccines, Papillomavirus vaccines, ATC code: J07BM02 Mechanism of action
Farmakoterapijska skupina: cjepiva, cjepiva protiv papilomavirusa, ATK oznaka: J07BM02 Mehanizam djelovanja
Pharmacodinamyc effect
Farmakodinamički učinak
Pharmacodynamic action
Farmakodinamički učinci
Pharmacodynamic activity was assessed through serial measurements of asparagine in serum (n=57) and cerebrospinal fluid (CSF) (n=50).
Farmakodinamička aktivnost ocijenjena je serijskim mjerenjima asparagina u serumu (n=57) i cerebrospinalnoj tekućini (n=50).
Pharmacodynamic and kinetic factors
Farmakodinamički i farmakokinetički čimbenici
Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days in 78.6% of cases (p<0.005 vs. levonorgestrel and vs. placebo) (see Table).
Farmakodinamički podaci pokazuju da čak i kada se uzme neposredno prije ovulacije (nakon što se razina LH već počela povećavati) ulipristalacetat može odgoditi prsnuće folikula za najmanje 5 dana u 78,6% slučajeva (p<0,005 naspram levonorgestrela i naspram placeba) (vidjeti tablicu).
Pharmacodynamic data suggest that at a dose of 0.2 mg/kg Replagal, the reductions in plasma Gb3 are more or less comparable between adolescents and young children (see section 5.1).
Farmakodinamički podaci upućuju da su pri dozi od 0,2 mg/kg Replagala smanjenja plazmatskog Gb3 manje-više usporediva kod adolescenata i mlađe djece (vidjeti dio 5.1).
Pharmacodynamic drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medicinal products may alter VIZAMYL image results.
Nisu provedena istraživanja farmakodinamičkih interakcija lijekova na bolesnicima kako bi se utvrdio opseg, ako postoji, u kojem istovremeno uzeti lijekovi mogu utjecati na rezultate snimaka dobivenih pomoću VIZAMYL-a.
Pharmacodynamic effects
Faramkodinamčki učinci
Pharmacodynamic effects
Farmakodinamički učinak
Pharmacodynamic effects
Farmakodinamični učinci
Pharmacodynamic effects
Farmakodinamski učinci
Pharmacodynamic effects
Farmakodinamčki učinci
Pharmacodynamic effects
Tromboembolija
Pharmacodynamic effects
UPUTE ZA UPORABU
Pharmacodynamic effects
Vrijeme od doze (minute)
Pharmacodynamic Endpoint
Farmakodinamički parametar
pharmacodynamic interaction.
Interakcija nije ispitivana.
Pharmacodynamic investigations of copper metabolism in patients with Wilson’s disease included determinations of net copper balance and radiolabelled copper uptake.
Farmakodinamska ispitivanja metabolizma bakra kod bolesnika s Wilsonovom bolesti uključivale su određivanje ukupne ravnoteže bakra i unos radiaktivno označenog bakra.
Pharmacodynamic investigations of copper metabolism in patients with Wilson’s disease included determinations of net copper balance and radiolabelled copper uptake.
Farmakodinamska ispitivanja pretrage metabolizma bakra kod bolesnika s Wilsonovom bolesti uključivale su određivanje ukupne ravnoteže bakra i unos radiaktivno označenog bakra.
Pharmacodynamic properties
Farmakodinamiĉka svojstva
Pharmacodynamic properties
Farmakodinamična svojstva
Pharmacodynamic studies were conducted in Wilson’s disease patients on the combination of Wilzin (50 mg three times daily) with ascorbic acid (1 g once daily), penicillamine (250 mg four times daily), and trientine (250 mg four times daily).
Provedene su farmakodinamske studije na bolesnicima s Wilsonovom bolesti koji su primali kombinaciju Wilzina (50 mg tri puta dnevno) s askorbatnom kiselinom (1 g jednom dnevno), penicilaminom (250 mg četiri puta dnevno), i trientinom (250 mg četiri puta dnevno).
pharmacoenhancement by means of
farmakokinetičko pojačanje u smislu
pharmacoenhancement by means of
lijekovima koji zahtijevaju
pharmacoenhancement since dosing
farmakokinetičko pojačanje jer
Pharmacogenetics
Biotransformacija
Pharmacogenetics
Propuštena doza:
Pharmacokine tic prope rties
Farmakokine tička svojstva
Pharmacokinetic /pharmacodynamic relationship
Farmakokinetički/farmakokinetički odnos
Pharmacokinetic analysis in one study was performed on nineteen of the patients, with a median (range) indinavir AUC 0-12hr, Cmax, and Cmin of 25,421 nM*h (21,489 – 36,236 nM*h), 5,758 nM (5,056 – 6,742 nM) and 239 (169 – 421 nM), respectively.
U jednom je ispitivanju provedena farmakokinetička analiza u 19 bolesnika, pri čemu je medijan (raspon) vrijednosti farmakokinetičkih parametara indinavira bio sljedeći: AUC 0-12h 25 421 nM*h (21 489 - 36 236 nM*h), Cmax 5758 nM (5056 – 6742 nM), a Cmin 239 (169 – 421 nM).
Pharmacokinetic behaviour of CellCept in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetika lijeka CellCept u starijih osoba (≥ 65 godina) nije formalno ispitivana.
Pharmacokinetic behaviour of CellCept in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetika lijeka CellCept u starijih osoba ( 65 godina) nije formalno ispitivana.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetika mofetilmikofenolata u starijih osoba (≥ 65 godina) nije formalno ispitivana.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly ( 65 years) has not been formally evaluated.
Farmakokinetika mofetilmikofenolata u starijih osoba ( 65 godina) nije formalno ispitivana.
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly (°65 years) has not been formally evaluated.
Farmakokinetika mofetilmikofenolata u starijih osoba (≥ 65 godina) nije formalno ispitivana.
pharmacokinetic change.
farmakokinetičke promjene.
Pharmacokinetic data are lacking in older CAPS patients.
Nema dovoljno farmakokinetičkih podataka za starije bolesnike s CAPS- om.
Pharmacokinetic data are not available for Tracleer in young children with this disease.
Nema farmakokinetičkih podataka za Tracleer kod male djece s ovom bolešću.
Pharmacokinetic data are not available in the elderly (over 65 years of age).
Nisu dostupni farmakokinetički podaci za stariju populaciju (stariju od 65 godina).
Pharmacokinetic data demonstrated that the teduglutide exposure of fetal rabbits and suckling rat pups was very low.
Farmakokinetički podaci pokazali su da je kod fetusa kunića i dojenih mladunaca štakora izloženost teduglutidu bila vrlo niska.